{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:07:53Z","timestamp":1780625273062,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019092","name":"Science Fund for Distinguished Young Scholars of Hunan Province","doi-asserted-by":"publisher","award":["No. 2023JJ60440"],"award-info":[{"award-number":["No. 2023JJ60440"]}],"id":[{"id":"10.13039\/501100019092","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Provincial Health Commission Research Program","award":["202303088786"],"award-info":[{"award-number":["202303088786"]}]},{"name":"Scientific Research Program of FuRong Laboratory","award":["No. 2023SK2108"],"award-info":[{"award-number":["No. 2023SK2108"]}]},{"name":"Clinical Medical Research Center for Viral Hepatitis of Hunan Province","award":["2023SK4009"],"award-info":[{"award-number":["2023SK4009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HBV-miR-3 is encoded by HBV and takes part in pathogenesis of HBV-related liver disease. Whether HBV-miR-3 has a relationship with HBV replication and is predictive of PegIFN-\u03b1 treatment response is still unknown. HBV-miR-3 quantification is based on qRT-PCR. The relationship of HBV-miR-3 and HBV replication, and predictive value of HBV-miR-3 were evaluated in a cohort of 650 HBeAg positive patients from a multi-center, randomized phase III clinical trial for the study of PegIFN-a2b. HBV-miR-3 is significantly positively related to HBVDNA, HBVpgRNA, HBeAg and HBsAg at baseline and at all the different time points during PegIFN-\u03b1 treatment. Both univariate regression analyses and multivariate logistic regression analyses showed HBV-miR-3 is a predictor of HBeAg seroconversion in the patients treated with PegIFN-\u03b1 at weeks of 0, 12, and 24. 70.0% of patients with HBV-miR-3\u2009&lt;\u20093log at week 12 achieved HBeAg seroconversion, otherwise, with HBV-miR-3\u2009&gt;\u20096log at week 12 no patient obtained HBeAg seroconversion. Conbination of HBV-miR-3 and HBeAg is more strongly predictive of HBeAg seroconversion (83.64%) at week 12. HBV-miR-3 is new biomarker for HBV replication and positively correlated to HBV replication. HBV-miR-3 is also an early predictor of HBeAg seroconversion in the patients treated with PegIFN-\u03b1.<\/jats:p>","DOI":"10.1038\/s41598-024-52060-0","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:02:17Z","timestamp":1705482137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["HBV-miR-3 is closely related to HBV replication and strongly predictive of HBeAg seroconversion in PegIFN-\u03b1 treated patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Zhenyu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"52060_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.coph.2021.07.008","volume":"60","author":"L Sandmann","year":"2021","unstructured":"Sandmann, L. & Cornberg, M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr. Opin. Pharmacol. 60, 232\u2013240. https:\/\/doi.org\/10.1016\/j.coph.2021.07.008 (2021).","journal-title":"Curr. Opin. Pharmacol."},{"key":"52060_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","volume":"66","author":"S Shimura","year":"2017","unstructured":"Shimura, S. et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. J. Hepatol. 66, 685\u2013692. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.009 (2017).","journal-title":"J. Hepatol."},{"key":"52060_CR3","doi-asserted-by":"publisher","first-page":"eaau7130","DOI":"10.1126\/sciadv.aau7130","volume":"5","author":"L Hou","year":"2019","unstructured":"Hou, L. et al. Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase. Sci. Adv. 5, eaau7130. https:\/\/doi.org\/10.1126\/sciadv.aau7130 (2019).","journal-title":"Sci. Adv."},{"key":"52060_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.14309\/ajg.0000000000000400","volume":"114","author":"K Zhou","year":"2019","unstructured":"Zhou, K. et al. Phase transition is infrequent among North American adults with e-antigen-negative chronic hepatitis B and low-level viremia. Am. J. Gastroenterol. 114, 1753\u20131763. https:\/\/doi.org\/10.14309\/ajg.0000000000000400 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"52060_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/2159-8290.CD-19-1006","volume":"10","author":"GA Hobbs","year":"2020","unstructured":"Hobbs, G. A. et al. Atypical KRAS(G12R) mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 10, 104\u2013123. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1006 (2020).","journal-title":"Cancer Discov."},{"key":"52060_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41418-018-0122-7","volume":"26","author":"J Sarhan","year":"2019","unstructured":"Sarhan, J. et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ. 26, 332\u2013347. https:\/\/doi.org\/10.1038\/s41418-018-0122-7 (2019).","journal-title":"Cell Death Differ."},{"key":"52060_CR7","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/jvh.13599","volume":"28","author":"F De Ridder","year":"2021","unstructured":"De Ridder, F. et al. Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance\u2014suggesting a valuable endpoint for early development HBV trials. J. Viral Hepat. 28, 1563\u20131569. https:\/\/doi.org\/10.1111\/jvh.13599 (2021).","journal-title":"J. Viral Hepat."},{"key":"52060_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbrc.2020.04.057","volume":"527","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. IFN-alpha2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx\/MSL2\/cccDNA\/HBV\/HBx in liver. Biochem. Biophys. Res. Commun. 527, 76\u201382. https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.057 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"52060_CR9","doi-asserted-by":"publisher","first-page":"779347","DOI":"10.3389\/fimmu.2021.779347","volume":"12","author":"A Song","year":"2021","unstructured":"Song, A. et al. Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive HBsAg carriers: A meta-analysis. Front. Immunol. 12, 779347. https:\/\/doi.org\/10.3389\/fimmu.2021.779347 (2021).","journal-title":"Front. Immunol."},{"key":"52060_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/hep.31850","volume":"74","author":"WB Ding","year":"2021","unstructured":"Ding, W. B. et al. HBV\/pregenomic RNA increases the stemness and promotes the development of HBV-related HCC through reciprocal regulation with insulin-like growth factor 2 mRNA-binding protein 3. Hepatology 74, 1480\u20131495. https:\/\/doi.org\/10.1002\/hep.31850 (2021).","journal-title":"Hepatology"},{"key":"52060_CR11","doi-asserted-by":"publisher","first-page":"733364","DOI":"10.3389\/fimmu.2021.733364","volume":"12","author":"J Ye","year":"2021","unstructured":"Ye, J. & Chen, J. Interferon and hepatitis B: Current and future perspectives. Front. Immunol. 12, 733364. https:\/\/doi.org\/10.3389\/fimmu.2021.733364 (2021).","journal-title":"Front. Immunol."},{"key":"52060_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41580-018-0059-1","volume":"20","author":"T Treiber","year":"2019","unstructured":"Treiber, T., Treiber, N. & Meister, G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat. Rev. Mol. Cell Biol. 20, 5\u201320. https:\/\/doi.org\/10.1038\/s41580-018-0059-1 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"52060_CR13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1080\/15476286.2017.1293770","volume":"14","author":"W Deng","year":"2017","unstructured":"Deng, W., Zhang, X., Ma, Z., Lin, Y. & Lu, M. MicroRNA-125b-5p mediates post-transcriptional regulation of hepatitis B virus replication via the LIN28B\/let-7 axis. RNA Biol. 14, 1389\u20131398. https:\/\/doi.org\/10.1080\/15476286.2017.1293770 (2017).","journal-title":"RNA Biol."},{"key":"52060_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01919-16","author":"X Yang","year":"2017","unstructured":"Yang, X. et al. Hepatitis B virus-encoded microRNA controls viral replication. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01919-16 (2017).","journal-title":"J. Virol."},{"key":"52060_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/jhc.s271091","volume":"7","author":"J Tang","year":"2020","unstructured":"Tang, J. et al. miR-3 encoded by hepatitis B virus downregulates PTEN protein expression and promotes cell proliferation. J. Hepatocell. Carcinoma 7, 257\u2013269. https:\/\/doi.org\/10.2147\/jhc.s271091 (2020).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"52060_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","volume":"77","author":"D Huang","year":"2022","unstructured":"Huang, D. et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J. Hepatol. 77, 42\u201354. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.021 (2022).","journal-title":"J. Hepatol."},{"key":"52060_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/17425255.2019.1678584","volume":"15","author":"ML Yeh","year":"2019","unstructured":"Yeh, M. L., Huang, J. F., Dai, C. Y., Yu, M. L. & Chuang, W. L. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opin. Drug Metab. Toxicol. 15, 779\u2013785. https:\/\/doi.org\/10.1080\/17425255.2019.1678584 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"52060_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/hep.24788","volume":"55","author":"J Guedj","year":"2012","unstructured":"Guedj, J., Dahari, H., Shudo, E., Smith, P. & Perelson, A. S. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 55, 1030\u20131037. https:\/\/doi.org\/10.1002\/hep.24788 (2012).","journal-title":"Hepatology"},{"key":"52060_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23722","volume":"52","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst, V. et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52, 454\u2013461. https:\/\/doi.org\/10.1002\/hep.23722 (2010).","journal-title":"Hepatology"},{"key":"52060_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3851\/IMP1841","volume":"16","author":"TC Tseng","year":"2011","unstructured":"Tseng, T. C. et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir. Ther. 16, 629\u2013637. https:\/\/doi.org\/10.3851\/IMP1841 (2011).","journal-title":"Antivir. Ther."},{"key":"52060_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s00535-016-1240-y","volume":"52","author":"A Urabe","year":"2017","unstructured":"Urabe, A. et al. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. J. Gastroenterol. 52, 366\u2013375. https:\/\/doi.org\/10.1007\/s00535-016-1240-y (2017).","journal-title":"J. Gastroenterol."},{"key":"52060_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2020.11.003","volume":"74","author":"A Suslov","year":"2021","unstructured":"Suslov, A. et al. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J. Hepatol. 74, 794\u2013800. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.003 (2021).","journal-title":"J. Hepatol."},{"key":"52060_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/apt.14376","volume":"47","author":"LY Mak","year":"2018","unstructured":"Mak, L. Y. et al. Review article: hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection. Aliment. Pharmacol. Ther. 47, 43\u201354. https:\/\/doi.org\/10.1111\/apt.14376 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"52060_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testoni","year":"2019","unstructured":"Testoni, B. et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 70, 615\u2013625. https:\/\/doi.org\/10.1016\/j.jhep.2018.11.030 (2019).","journal-title":"J. Hepatol."},{"key":"52060_CR25","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/hep.30325","volume":"69","author":"S Liu","year":"2019","unstructured":"Liu, S., Zhou, B., Valdes, J. D., Sun, J. & Guo, H. Serum hepatitis B virus RNA: A new potential biomarker for chronic hepatitis B virus infection. Hepatology 69, 1816\u20131827. https:\/\/doi.org\/10.1002\/hep.30325 (2019).","journal-title":"Hepatology"},{"key":"52060_CR26","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","volume":"66","author":"K Giersch","year":"2017","unstructured":"Giersch, K., Allweiss, L., Volz, T., Dandri, M. & Lutgehetmann, M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J. Hepatol. 66, 460\u2013462. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.028 (2017).","journal-title":"J. Hepatol."},{"key":"52060_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s12072-020-10015-3","volume":"14","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: A longitudinal cohort study. Hepatol. Int. 14, 212\u2013224. https:\/\/doi.org\/10.1007\/s12072-020-10015-3 (2020).","journal-title":"Hepatol. Int."},{"key":"52060_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7150\/thno.10636","volume":"5","author":"FQ Hou","year":"2015","unstructured":"Hou, F. Q. et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics 5, 218\u2013226. https:\/\/doi.org\/10.7150\/thno.10636 (2015).","journal-title":"Theranostics"},{"key":"52060_CR29","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2174\/2211536608666191104105334","volume":"9","author":"T Chavalit","year":"2020","unstructured":"Chavalit, T. et al. Hepatitis B virus-encoded microRNA (HBV-miR-3) regulates host gene PPM1A related to hepatocellular carcinoma. Microrna 9, 232\u2013239. https:\/\/doi.org\/10.2174\/2211536608666191104105334 (2020).","journal-title":"Microrna"},{"key":"52060_CR30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.21037\/atm-22-2119","volume":"10","author":"W Gan","year":"2022","unstructured":"Gan, W. et al. The relationship between serum exosome HBV-miR-3 and current virological markers and its dynamics in chronic hepatitis B patients on antiviral treatment. Ann. Transl. Med. 10, 536. https:\/\/doi.org\/10.21037\/atm-22-2119 (2022).","journal-title":"Ann. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52060-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52060-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52060-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:11:10Z","timestamp":1705482670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-52060-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52060"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-52060-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3264285\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1502"}}